Pancreatic neuroendocrine tumors: Biology, diagnosis, and treatment

Chinese Journal of Cancer

Volumn 32, Issue 6, 2013, Pages 312-324

  Ro, Cynthia ^a   Chai, Wanxing ^a   Yu, Victoria E ^a   Yu, Run ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Gastrinoma; Glucagonoma; Insulinoma; Mahvash disease; Multiple endocrine neoplasia syndrome type 1; Non functioning; Pancreatic neuroendocrine tumors; VIPoma

Indexed keywords

ALCOHOL; ALPHA INTERFERON; ANGIOPEPTIN; CAPECITABINE; CHROMOGRANIN A; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DAXX PROTEIN; ETOPOSIDE; EVEROLIMUS; FLUORODEOXYGLUCOSE; FLUOROURACIL; GASTRIN; INSULIN; NEURON SPECIFIC ENOLASE; OCTREOTIDE; PANCREAS POLYPEPTIDE; PANCREASTATIN; PASIREOTIDE; PROINSULIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

BILE DUCT DISEASE; CANCER GRADING; CHEMOEMBOLIZATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; GASTRINOMA; GENE MUTATION; GLUCAGONOMA; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HYPERGLYCEMIA; INSULINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MICROWAVE THERAPY; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS SURGERY; PANCREATIC NEUROENDOCRINE TUMOR; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMATOSTATINOMA; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VIPOMA; VON HIPPEL LINDAU DISEASE; WATCHFUL WAITING;

COMBINED MODALITY THERAPY; GASTRINOMA; GLUCAGONOMA; HUMANS; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; VIPOMA; VON HIPPEL-LINDAU DISEASE;

EID: 84878947301     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10295     Document Type: Review

References (160)

1. Rindi G, Bordi C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer, 2003, 10:427-436.
2. Massironi S, Sciola V, Peracchi M, et al. Neuroendocrine tumors of the gastro-en tero-pa ncreatic system. World J Gastroenterol, 2008,14:5377-5384.
3. Ehehalt F, Saeger HD, Schmidt CM, et al. Neuroendocrine tumors of the pancreas. Oncologist, 2009,14:456-467.
4. Yao JC, Hassan M, Phan A, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 2008,26:3063-3072.
5. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes, 2009,16:72-78.
6. Antonello D, Gobbo S, Corbo V, et al. Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma. Pancreatology, 2009,9:25-33.
7. Speel EJ, Scheidweiler AF, Zhao J, et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas. Cancer Res, 2009,61:5186-5192.
8. Zhao J, Moch H, Scheidweiler AF, et al. Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer, 2001,32:364-372.
9. Chung DC, Smith AP, Louis DN, et al. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest, 1997,100: 404-410.
10. Wild A, Langer P, Celik I, et al. Chromosome 22q in pancreatic endocrine tumors: identification of a homozygous deletion and potential prognostic associations of allelic deletions. Eur J Endocrinol, 2002,147:507-513.
11. Beghelli S, Pelosi G, Zamboni G, et al. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol, 1998,186:41-50.
12. Chung DC, Smith AP, Louis DN, et al. Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clin Endocrinol, 1997,47:523-528.
13. Lohmann DR, Funk A, Niedermeyer HP, et al. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol Incl Mol Pathol, 1993,64:293-296.
14. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res, 1994, 54:1556-1560.
15. Lam KY, Lo CY. Role of p53 tumor suppressor gene in pancreatic endocrine tumors of Chinese patients. Am J Gastroenterol, 1998,93:1232-1235.
16. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Archiv, 1996,429:323-333.
17. Bartsch DK, Kersting M, Wild A, et al. Low frequency of p16 (INK4a) alterations in insulinomas. Digestion, 2000,62:171-177.
18. Chung DC, Brown SB, Graeme-Cook F, et al. Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab, 2000,85:4373-4378.
19. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 2011,331:1199-1203.
20. Vortmeyer AO, Huang S, Lubensky I, et al. Non-is let origin of pancreatic islet cell tumors. J Clin Endocrinol Metab, 2004,89: 1934-1938.
21. Perren A, Anlauf M, Henopp T, et al. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab, 2007, 92:1118-1128.
22. Anlauf M, Perren A, Kloppel G. Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology, 2007,74:279-284.
23. Kloppel G, Anlauf M, Perren A. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol, 2007,18:150-155.
24. Thompson NW, Lloyd RV, Nishiyama RH, et al. MEN I pancreas: a histological and immunohistochemical study. World J Surg, 1984,8:561-574.
25. Lubensky IA, Pack S, Ault D, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol, 1998,153:223-231.
26. Anlauf M, Perren A, Henopp T, et al. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut, 2007,56:637-644.
27. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A, 2001,98:1118-1123.
28. Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol, 2011,8:54-64.
29. Pritchard DM. Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1. Gut, 2007,56:606-607.
30. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci, 1991, 36:933-942.
31. Sakurai A, Katai M, Yamashita K, et al. Long-te rm follow-up of patients with multiple endocrine neoplasia type 1. Endocr J, 2007,54:295-302.
32. Daví M V, Boninsegna L, Dalle Carbonare L, et al. Presentation and outcome of pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1 syndrome. Neuroendocrinology, 2011,94:58-65.
33. Broder LE, Carter SK. Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med, 1973,79:101-107.
34. Cubilla AL, Hajdu SI. Islet cell carcinoma of the pancreas. Arch Pathol, 1975,99:204-207.
35. La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol, 2009,40:30-40.
36. Schmitt AM, Anlauf M, Rousson V, et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol, 2007,31:1677-1682.
37. Mao C, el Attar A, Domenico DR, et al. Carcinoid tumors of the pancreas. Status report based on two cases and review of the world s literature. Int J Pancreatol, 1998,23:153-164.
38. Zhu L, Domenico DR, Howard JM. Metastatic pancreatic neuroendocrine carcinoma causing Cushing's syndrome. ACTH secretion by metastases 3 years after resection of nonfunctioning primary cancer. Int J Pancreatol, 1996,19:205-208.
39. Saeger W, Reincke M, Scholz GH, et al. Ectopic ACTH-or CRH-se creting tumors in Cushing's syndrome. Zentralbl Pathol, 1993,139:157-163.
40. Milanesi A, Yu R, Geller SA, et al. Concurrent primary hyper-parathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1. Pancreas, 2011,40:634-637.
41. Vacher-Coponat H, Opris A, Denizot A, et al. Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour. Nephrol Dial Transplant, 2005,20:2832-2835.
42. Doga M, Bonadonna S, Burattin A, et al. Ectopic secretion of growth hormone-re leasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Ann Oncol, 2001,2:S89-S94.
43. Melmed S, Ezrin C, Kovacs K, et al. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med, 1985,312:9-17.
44. Machens A, Haedecke J, Hinze R, et al. Hypercalcitoninemia in a sporadic asymptomatic neuroendocrine tumor of the pancreatic tail. Dig Surg, 2000,17:522-524.
45. Corbetta S, Peracchi M, Cappiello V, et al. Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. J Clin Endocrinol Metab, 2003,88:3117-3120.
46. Bidart JM, Baudin E, Troalen F, et al. Eutopic and ectopic production of glycoprotein hormones alpha and beta subunits. Ann Endocrinol (Paris), 1997,58:125-128.
47. Langer P, Bartsch D, Gerdes B, et al. Renin producing neuroendocrine pancreatic carcinoma-a case report and review of the literature. Exp Clin Endocrinol Diabetes, 2002, 110:43-49.
48. Miehle K, Tannapfel A, Lamesch P, et al. Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence. J Clin Endocrinol Metab, 2004,89:3731-3736.
49. Kaltsas G, Androulakis II, de Herder WW, et al. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer, 2010,17:R173-R193.
50. Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am, 2011,40:111-134.
51. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion, 2000,62 Suppl 1:33-38.
52. ODorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas, 2010,39:611-616.
53. Sanduleanu S, De Bruíe A, Stridsberg M, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-lik e cell hyperplasia during acid-su ppressive therapy. Eur J Clin Invest, 2001,31:802-811.
54. Peracchi M, Gebbia C, Basilisco G, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-lik e cell lesions and gastric carcinoids. Eur J Endocrinol, 2005,152:443-448.
55. Raman SP, Hruban RH, Cameron JL, et al. Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics. AJR Am J Roentgenol, 2012,199:309-318.
56. Debray MP, Geoffroy O, Laissy JP, et al. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol, 2001,74:1065-1070.
57. Krausz Y, Bar-Ziv J, de Jong RB, et al. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol, 1998,93:66-70.
58. Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumours with [111In] DTPA-oc treotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM, 1998,91:295-301.
59. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med, 1998,25: 79-83
60. Ambrosini V, Tomassetti P, Franchi R, et al. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging, 2010,54:16-23.
61. Krausz Y, Freedman N, Rubinstein R, et al. 68Ga-D OTA-N OC PET/CT imaging of neuroendocrine tumors: comparison with 111In-D TPA-oc treotide (OctreoScan). Mol Imaging Biol, 2011, 13:583-593.
62. Hofman MS, Kong G, Neels OC, et al. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol, 2012,56:40-47.
63. Gupta RK, Naran S, Lallu S, et al. Fine needle aspiration diagnosis of neuroendocrine tumors in the liver. Pathology, 2000, 32:16-20
64. Atiq M, Bhutani MS, Bektas M, et al. EUS-FN A for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci, 2012,57:791-800.
65. Collins BT, Cramer HM. Fine-ne edle aspiration cytology of islet cell tumors. Diagn Cytopathol, 1996,15:37-45.
66. Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-di fferentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-ne edle aspiration biopsy specimens. Cancer Cytopathol, 2011,119:193-201.
67. Verbeke CS. Endocrine tumours of the pancreas. Histopathology, 2010,56:669-682.
68. Klöpel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer, 2011,18 Suppl 1:S1-S16.
69. Kaklamanos M, Karoumpalis I, Salla C, et al. Diagnostic accuracy and clinical significance of the fine needle aspiration Ki-67 labelling index in pancreatic endocrine tumours. Endocr Relat Cancer, 2011,18:L1-L3.
70. Kvols LK, Revisiting CG. Moertel's land of small tumors. J Clin Oncol, 2008, 26:5005-5007.
71. Yu R. Radiotherapy: radioactive somatostatin analog therapy against carcinoids. Nat Rev Endocrinol, 2010,6:428-430.
72. Ong SL, Garcea G, Pollard CA, et al. A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology, 2009,9:583-600.
73. Konstantinidis IT, Dursun A, Zheng H, et al. Metastatic tumors in the pancreas in the modern era. J Am Coll Surg, 2010,211: 749-753.
74. de Herder WW, Mazzaferro V, Tavecchio L, et al. Multidisciplinary approach for the treatment of neuroendocrine tumors. Tumori, 2010,96:833-846.
75. Tsuchikawa T, Hirano S, Tanaka E, et al. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors-a single center experience. Hepatogastroenterology, 2012,59:2623-2626.
76. Nguyen SQ, Angel LP, Divino CM, et al. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol, 2007,96:397-403.
77. Fendrich V, Waldmann J, Bartsch DK, et al. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol, 2009,6:419-428.
78. Proye C. Natural history of liver metastasis of gastroentero-pancreatic neuroendocrine tumors: place for chemoembo-lization. World J Surg, 2001,25:685-688.
79. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-m icrospheres: early results in 148 patients. Am J Clin Oncol, 2008,31:271-279.
80. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer, 2005,104:1590-1602.
81. Strosberg JR, Choi J, Cantor AB, et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control, 2006,13:72-78.
82. Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery, 2007,142:10-19.
83. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol, 2005,28:409-221.
84. Frilling A, Sotiropoulos GC, Li J, et al. Multimodal management of neuroendocrine liver metastases. HPB (Oxford), 2010,12: 361-379.
85. ODorisio TM, Gaginella TS, Mekhjian HS, et al. Somatostatin and analogues in the treatment of VIPoma. Ann N Y Acad Sci, 1988,527:528-535.
86. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci, 1989,34:28S-39S.
87. Lamberts SW. Somatostatin analogs in the management of gastrointestinal tumors. Horm Res, 1988,29:118-120.
88. Sidéris L, Dubép, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist, 2012,17:747-755.
89. Kvols L, Oberg KE, ODorisio T, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a Phase II study. Endocr Relat Cancer, 2012,19:657-666
90. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol, 1999,10 Suppl 2:S31-S38.
91. Fazio N, de Braud F, Delle Fave G, et al. Interferonal pha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol, 2007,18:13-19.
92. Yao JC, Shah MH, Ito T, et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011,364:514-523.
93. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011,364:501-513.
94. Strosberg JR, Fine RL, Choi J, et al. First-lin e chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011,117:268-275.
95. Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol, 2010,40:313-318.
96. Turner NC, Strauss SJ, Sarker D, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer, 2010,102:1106-1112.
97. Pavel ME, Wiedenmann B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011,43:844-853.
98. Oberstein PE, Saif MW. Update on novel therapies for pancreatic neuroendocrine tumors. JOP, 2012, 13:372-375.
99. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-D OTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol, 2008,26:2124-2130.
100. Bushnell DL Jr, ODorisio TM, ODorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol, 2010,28:1652-1659.
101. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation, 1998, 66:1307-1312.
102. Gulati AP, Saif MW. Is there a role for liver transplantation in metastatic pancreatic neuroendocrine tumors (PNET)? JOP, 2012,13:320-321.
103. Lillemoe KD, Kaushal S, Cameron JL, et al. Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg, 1999,229:693-700.
104. Crucitti F, Doglietto G, Bellantone R, et al. Digestive and nutritional consequences of pancreatic resections. The classical vs the pylorus-sp aring procedure. Int J Pancreatol, 1995,17: 37-45.
105. Kim SJ, Kim JW, Han SW, et al. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer, 2010,10:448.
106. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol, 2005, 19:783-798.
107. Zhao YP, Zhan HX, Zhang TP, et al. Surgical management of patients with insulinomas: result of 292 cases in a single institution. J Surg Oncol, 2011,103:169-174.
108. Service FJ, Natt N, Thompson GB, et al. Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab, 1999,84:1582-1589.
109. Service FJ, Natt N. The prolonged fast. J Clin Endocrinol Metab, 2000,85:3973-3974.
110. Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab, 2009, 94:1074-1080.
111. Sotoudehmanesh R, Hedayat A, Shirazian N, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine, 2007,31:238-241.
112. Wong M, Isa SH, Zahiah M, et al. Intraoperative ultrasound with palpation is still superior to intraar terial calcium stimulation test in localising insulinoma. World J Surg, 2007,31:586-592.
113. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1receptor imaging for localization of insulinomas. J Clin Endocrinol Metab, 2009,94:4398-4405
114. Hirshberg B, Cochran C, Skarulis MC, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer, 2005, 104:264-272.
115. Bourcier ME, Sherrod A, DiGuardo M, et al. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-se creting islet cell tumor and metastases. J Clin Endocrinol Metab, 2009,94:3157-3162.
116. Ong GS, Henley DE, Hurley D, et al. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol, 2010,162: 1001-1008.
117. Mei M, Deng D, Liu TH, et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J Clin Endocrinol Metab, 2009,94:3448-3457.
118. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep, 2004,6:454-463.
119. Cameron AJ, Hoffman HN 2nd. Zollinger-Ellison syndrome. Clinical features and long-te rm follow-up. Mayo Clin Proc, 1974,49:44-51.
120. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore), 2006,85:331-364.
121. Stabile BE, Morrow DJ, Passaro E Jr. The gastrinoma triangle: operative implications. Am J Surg, 1984,147:25-31.
122. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore), 2006,85:295-330.
123. Prinz RA. Localization of gastrinomas. Int J Pancreatol, 1996, 19:79-91.
124. Pfannenberg AC, Burkart C, Kröer SM, et al. Dual-phase multidetector thin-se ction CT in detecting duodenal gastrinoma. Abdom Imaging, 2005,30:543-547.
125. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg, 2006,244:410-419.
126. Campana D, Piscitelli L, Mazzotta E, et al. Zollinger-Ellison syndrome. Diagnosis and therapy. Minerva Med, 2005,96:187-206.
127. Cisco RM, Norton JA. Surgery for gastrinoma. Adv Surg, 2007, 41:165-176.
128. Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-ty pe 1 (MEN1). Surg Oncol, 2003,12:145-151.
129. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology, 2000,118:696-704.
130. Mekhjian HS, ODorisio TM. VIPoma syndrome. Semin Oncol, 1987,14:282-291.
131. Park SK, ODorisio MS, ODorisio TM. Vasoactive intestinal polypeptide-se creting tumours: biology and therapy. Baillieres Clin Gastroenterol, 1996,10:673-696.
132. Peng SY, Li JT, Liu YB, et al. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas, 2004,28:93-97.
133. Koch TR, Michener SR, Go VL. Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea. Gastroenterology, 1991,100:99-106.
134. Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg, 2008,12:382-393.
135. Wermers RA, Fatourechi V, Wynne AG, et al. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore), 1996,75:53-63.
136. Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol, 2007,24:330-337.
137. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci, 2001,321:306-320.
138. Boden G, Owen OE. Familial hyperglucagonemia-an autosomal dominant disorder. N Engl J Med, 1977,296:534-538.
139. Yu R, Nissen NN, Dhall D, et al. Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas. Pancreas, 2008, 36:428-431.
140. Ouyang D, Dhall D, Yu R. Pathologic pancreatic endocrine cell hyperplasia. World J Gastroenterol, 2011,17:137-143.
141. Boden G, Ryan IG, Eisenschmid BL, et al. Treatment of inoperable glucagonoma with the long-ac ting somatostatin analogue SMS 201-995. N Engl J Med, 1986,314:1686-1689.
142. Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery, 2001,130:1078-1085.
143. Kouvaraki MA, Solorzano CC, Shapiro SE, et al. Surgical treatment of non-fu nctioning pancreatic islet cell tumors. J Surg Oncol, 2005,89:170-185.
144. Kuo SC, Gananadha S, Scarlett CJ, et al. Sporadic pancreatic polypeptide secreting tumors (PPomas) of the pancreas. World J Surg, 2008,32:1815-1822.
145. Marx SJ, Agarwal SK, Kester MB, et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res, 1999,54:397-439.
146. Agarwal SK, Kennedy PA, Scacheri PC, et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res, 2005,37:369-374.
147. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci, 2004,1014: 189-198.
148. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab, 2001,86:5658-5671.
149. Tonelli F, Giudici F, Fratini G, et al. Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr Pract, 2011,17 Suppl 3:33-40.
150. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab, 2012, 97:2990-3011.
151. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet, 2011,19:617-623.
152. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer, 2002,2:673-682
153. Shuin T, Yamazaki I, Tamura K, et al. Recent advances in ideas on the molecular pathology and clinical aspects of Von Hippel-Lindau disease. Int J Clin Oncol, 2004,9:283-287.
154. Libutti SK, Choyke PL, Bartlett DL, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery, 1998,124:1153-1159.
155. Tamura K, Nishimori I, Ito T, et al. Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease. World J Gastroenterol, 2010,16:4515-4518.
156. Zhou C, Dhall D, Nissen NN, et al. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas, 2009,38:941-946.
157. Yu R, Wawrowsky K, Zhou C. A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. Endocrinol Nutr, 2011,58:258-266.
158. Yu R, Dhall D, Nissen NN, et al. Pancreatic neuroendocrine tumors in glucagon receptor-de ficient mice. PLoS One, 2011,6: e23397.
159. Yu R, Ren SG, Miroha J. Glucagon receptor is required for long-te rm survival: a natural history study of the Mahvash disease in a murine model. Endocrinol Nutr, 2012,59:523-530.
160. Yu R, Chen CR, Liu X, et al. Rescue of a pathogenic mutant human glucagon receptor by pharmacological chaperones. J Mol Endocrinol, 2012,49:69-78.